Drug Trial Radar · NCT07481747
Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1)
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
2,539
Planned (sponsor's estimate)
Start
Feb 2, 2026
Primary completion
Feb 14, 2027
Study completion Mar 17, 2028
Sponsor
- Lead sponsor
- Hudson BiotechIndustry
- Sponsor type
- Industry
- First posted
- Mar 19, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase 3 study evaluates the efficacy and safety of once-weekly subcutaneous tirzepatide (a dual GIP and GLP-1 receptor agonist) at 5 mg, 10 mg, or 15 mg versus placebo, each used with a reduced-calorie diet and increased physical activity, in adults without type 2 diabetes who have obesity or are overweight with weight-related comorbidities. The primary efficacy assessment is at Week 72. Participants with prediabetes at randomization may continue in an additional long-term treatment period to assess progression to type 2 diabetes and longer-term weight outcomes.
Conditions
- Obesity
- Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities
Interventions
TirzepatideDrug
(once-weekly SC injection; doses 5/10/15 mg)
PlaceboDrug
(once-weekly SC injection)
Reduced-calorie dietBehavioral
increased physical activity counseling
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean percent change in body weight from randomizationTime frame: 72 Weeks
- Percentage of participants achieving ≥5% body weight reduction from randomizationTime frame: 72 Weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University Shenzhen Hospital
Shenzhen, Guangdong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.